ID   INSR_HUMAN              Reviewed;        1382 AA.
AC   P06213; Q17RW0; Q59H98; Q9UCB7; Q9UCB8; Q9UCB9;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 4.
DT   02-NOV-2010, entry version 163.
DE   RecName: Full=Insulin receptor;
DE            Short=IR;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD220;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit alpha;
DE   Contains:
DE     RecName: Full=Insulin receptor subunit beta;
DE   Flags: Precursor;
GN   Name=INSR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANTS GLY-2;
RP   HIS-171; THR-448 AND LYS-492.
RX   MEDLINE=85176928; PubMed=2859121; DOI=10.1016/0092-8674(85)90334-4;
RA   Ebina Y., Ellis L., Jarnagin K., Edery M., Graf L., Clauser E.,
RA   Ou J.-H., Masiarz F., Kan Y.W., Goldfine I.D., Roth R.A., Rutter W.J.;
RT   "The human insulin receptor cDNA: the structural basis for hormone-
RT   activated transmembrane signalling.";
RL   Cell 40:747-758(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PROTEIN SEQUENCE OF 28-49
RP   AND 763-782, GLYCOSYLATION AT ASN-43 AND ASN-769, AND VARIANT GLY-2.
RX   MEDLINE=85137889; PubMed=2983222; DOI=10.1038/313756a0;
RA   Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M.,
RA   Dull T.J., Gray A., Coussens L., Liao Y.-C., Tsubokawa M., Mason A.,
RA   Seeburg P.H., Grunfeld C., Rosen O.M., Ramachandran J.;
RT   "Human insulin receptor and its relationship to the tyrosine kinase
RT   family of oncogenes.";
RL   Nature 313:756-761(1985).
RN   [3]
RP   SEQUENCE REVISION TO 899-900.
RA   Chen E.Y.;
RL   Submitted (JUL-1985) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-2.
RC   TISSUE=Fetal liver;
RX   MEDLINE=91006864; PubMed=2210055;
RA   Seino S., Seino M., Bell G.I.;
RT   "Human insulin-receptor gene. Partial sequence and amplification of
RT   exons by polymerase chain reaction.";
RL   Diabetes 39:123-128(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT
RP   GLY-2.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   MEDLINE=88058985; PubMed=3680248;
RA   Araki E., Shimada F., Uzawa H., Mori M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene. Evidence for promoter activity.";
RL   J. Biol. Chem. 262:16186-16191(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   MEDLINE=90032206; PubMed=2806055; DOI=10.1016/0168-8227(89)90085-5;
RA   Araki E., Shimada F., Fukushima H., Mori M., Shichiri M., Ebina Y.;
RT   "Characterization of the promoter region of the human insulin receptor
RT   gene.";
RL   Diabetes Res. Clin. Pract. 7:S31-S33(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RX   MEDLINE=89380228; PubMed=2777789;
RA   Tewari D.S., Cook D.M., Taub R.;
RT   "Characterization of the promoter region and 3' end of the human
RT   insulin receptor gene.";
RL   J. Biol. Chem. 264:16238-16245(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-33, AND VARIANT GLY-2.
RC   TISSUE=Skin fibroblast;
RX   MEDLINE=91125373; PubMed=2280779;
RA   McKeon C., Moncada V., Pham T., Salvatore P., Kadowaki T., Accili D.,
RA   Taylor S.I.;
RT   "Structural and functional analysis of the insulin receptor
RT   promoter.";
RL   Mol. Endocrinol. 4:647-656(1990).
RN   [11]
RP   PROTEIN SEQUENCE OF 28-44; 192-205; 299-314; 610-627 AND 763-780,
RP   ENZYME REGULATION, AND BINDING OF MANGANESE.
RC   TISSUE=Placenta;
RX   MEDLINE=91009374; PubMed=2211730;
RA   Xu Q.-Y., Paxton R.J., Fujita-Yamaguchi Y.;
RT   "Substructural analysis of the insulin receptor by microsequence
RT   analyses of limited tryptic fragments isolated by sodium dodecyl
RT   sulfate-polyacrylamide gel electrophoresis in the absence or presence
RT   of dithiothreitol.";
RL   J. Biol. Chem. 265:18673-18681(1990).
RN   [12]
RP   PROTEIN SEQUENCE OF 28-45 AND 763-782, FUNCTION, AND FORMATION OF A
RP   HYBRID RECEPTOR WITH IGF1R.
RC   TISSUE=Placenta;
RX   MEDLINE=94079885; PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-
RT   I/insulin hybrid receptors by protein microsequencing and
RT   purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 538-1382 (ISOFORM SHORT).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 728-772 (ISOFORM LONG), AND ALTERNATIVE
RP   SPLICING.
RX   MEDLINE=89165872; PubMed=2538124; DOI=10.1016/0006-291X(89)92439-X;
RA   Seino S., Bell G.I.;
RT   "Alternative splicing of human insulin receptor messenger RNA.";
RL   Biochem. Biophys. Res. Commun. 159:312-316(1989).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 744-823 (ISOFORM LONG), TISSUE
RP   SPECIFICITY, LIGAND-BINDING, AND AUTOPHOSPHORYLATION.
RX   MEDLINE=90316094; PubMed=2369896;
RA   Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A.,
RA   McClain D.A.;
RT   "Functionally distinct insulin receptors generated by tissue-specific
RT   alternative splicing.";
RL   EMBO J. 9:2409-2413(1990).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 895-1085.
RX   MEDLINE=89252471; PubMed=2566545;
RA   Elbein S.C.;
RT   "Molecular and clinical characterization of an insertional
RT   polymorphism of the insulin-receptor gene.";
RL   Diabetes 38:737-743(1989).
RN   [17]
RP   PROTEIN SEQUENCE OF 927-956; 981-1019; 1182-1194 AND 1352-1369, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Placenta;
RX   MEDLINE=88326279; PubMed=3166375;
RA   Tavare J.M., Denton R.M.;
RT   "Studies on the autophosphorylation of the insulin receptor from human
RT   placenta. Analysis of the sites phosphorylated by two-dimensional
RT   peptide mapping.";
RL   Biochem. J. 252:607-615(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1006-1123.
RX   MEDLINE=89298408; PubMed=2544997; DOI=10.1126/science.2544997;
RA   Taira M., Taira M., Hashimoto N., Shimada F., Suzuki Y., Kanatsuka A.,
RA   Nakamura F., Ebina Y., Tatibana M., Makino H.;
RT   "Human diabetes associated with a deletion of the tyrosine kinase
RT   domain of the insulin receptor.";
RL   Science 245:63-66(1989).
RN   [19]
RP   PARTIAL PROTEIN SEQUENCE.
RX   MEDLINE=88190050; PubMed=3447155;
RA   Fujita-Yamaguchi Y., Hawke D., Shively J.E., Choi S.;
RT   "Partial amino acid sequence analyses of human placental insulin
RT   receptor.";
RL   Protein Seq. Data Anal. 1:3-6(1987).
RN   [20]
RP   MUTAGENESIS OF LYS-1057.
RX   MEDLINE=87118237; PubMed=3101064; DOI=10.1073/pnas.84.3.704;
RA   Ebina Y., Araki E., Taira M., Shimada F., Mori M., Craik C.S.,
RA   Siddle K., Pierce S.B., Roth R.A., Rutter W.J.;
RT   "Replacement of lysine residue 1030 in the putative ATP-binding region
RT   of the insulin receptor abolishes insulin- and antibody-stimulated
RT   glucose uptake and receptor kinase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:704-708(1987).
RN   [21]
RP   MUTAGENESIS OF TYR-999.
RX   MEDLINE=88311065; PubMed=2842060; DOI=10.1016/S0092-8674(88)80008-4;
RA   White M.F., Livingston J.N., Backer J.M., Lauris V., Dull T.J.,
RA   Ullrich A., Kahn C.R.;
RT   "Mutation of the insulin receptor at tyrosine 960 inhibits signal
RT   transmission but does not affect its tyrosine kinase activity.";
RL   Cell 54:641-649(1988).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   MEDLINE=92337603; PubMed=1321605; DOI=10.1016/S0006-291X(05)80799-5;
RA   Dickens M., Tavare J.M.;
RT   "Analysis of the order of autophosphorylation of human insulin
RT   receptor tyrosines 1158, 1162 and 1163.";
RL   Biochem. Biophys. Res. Commun. 186:244-250(1992).
RN   [23]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-541.
RX   MEDLINE=93112026; PubMed=1472036; DOI=10.1016/0006-291X(92)92250-2;
RA   Schaeffer L., Ljungqvist L.;
RT   "Identification of a disulfide bridge connecting the alpha-subunits of
RT   the extracellular domain of the insulin receptor.";
RL   Biochem. Biophys. Res. Commun. 189:650-653(1992).
RN   [24]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=8452530;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH PIK3R1.
RX   PubMed=8276809;
RA   Van Horn D.J., Myers M.G. Jr., Backer J.M.;
RT   "Direct activation of the phosphatidylinositol 3'-kinase by the
RT   insulin receptor.";
RL   J. Biol. Chem. 269:29-32(1994).
RN   [26]
RP   INTERACTION WITH IRS1 AND SHC1, AND MUTAGENESIS OF LEU-991; TYR-992;
RP   ASN-996; 996-ASN-PRO-997; PRO-997; TYR-999; LEU-1000 AND ALA-1002.
RX   MEDLINE=96007458; PubMed=7559478; DOI=10.1074/jbc.270.40.23258;
RA   He W., O'Neill T.J., Gustafson T.A.;
RT   "Distinct modes of interaction of SHC and insulin receptor substrate-1
RT   with the insulin receptor NPEY region via non-SH2 domains.";
RL   J. Biol. Chem. 270:23258-23262(1995).
RN   [27]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, AND MUTAGENESIS OF ASN-996;
RP   PRO-997; GLU-998; TYR-999 AND LYS-1057.
RX   PubMed=7537849;
RA   Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.;
RT   "Phosphotyrosine-dependent interaction of SHC and insulin receptor
RT   substrate 1 with the NPEY motif of the insulin receptor via a novel
RT   non-SH2 domain.";
RL   Mol. Cell. Biol. 15:2500-2508(1995).
RN   [28]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9355755;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [29]
RP   FORMATION OF A HYBRID RECEPTOR WITH IGF1R, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/S0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors
RT   in human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [30]
RP   INTERACTION WITH SORBS1.
RX   MEDLINE=21269187; PubMed=11374898; DOI=10.1006/geno.2001.6541;
RA   Lin W.-H., Huang C.-J., Liu M.-W., Chang H.-M., Chen Y.-J., Tai T.-Y.,
RA   Chuang L.-M.;
RT   "Cloning, mapping, and characterization of the human sorbin and SH3
RT   domain containing 1 (SORBS1) gene: a protein associated with c-Abl
RT   during insulin signaling in the hepatoma cell line Hep3B.";
RL   Genomics 74:12-20(2001).
RN   [31]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=12138094; DOI=10.1074/jbc.M202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [32]
RP   INTERACTION WITH GRB10.
RX   PubMed=12493740; DOI=10.1074/jbc.M208518200;
RA   Wick K.R., Werner E.D., Langlais P., Ramos F.J., Dong L.Q.,
RA   Shoelson S.E., Liu F.;
RT   "Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-
RT   phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the
RT   association of IRS-1/IRS-2 with the insulin receptor.";
RL   J. Biol. Chem. 278:8460-8467(2003).
RN   [33]
RP   INTERACTION WITH SOCS7.
RX   PubMed=16127460; DOI=10.1172/JCI23853;
RA   Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D.,
RA   Rothman P.B.;
RT   "Deletion of SOCS7 leads to enhanced insulin action and enlarged
RT   islets of Langerhans.";
RL   J. Clin. Invest. 115:2462-2471(2005).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1189, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=15951569; DOI=10.1074/mcp.M500089-MCP200;
RA   Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,
RA   Lauffenburger D.A., White F.M.;
RT   "Time-resolved mass spectrometry of tyrosine phosphorylation sites in
RT   the epidermal growth factor receptor signaling network reveals dynamic
RT   modules.";
RL   Mol. Cell. Proteomics 4:1240-1250(2005).
RN   [35]
RP   DEPHOSPHORYLATION BY PTPRE.
RX   PubMed=15738637; DOI=10.2108/zsj.22.169;
RA   Nakagawa Y., Aoki N., Aoyama K., Shimizu H., Shimano H., Yamada N.,
RA   Miyazaki H.;
RT   "Receptor-type protein tyrosine phosphatase epsilon (PTPepsilonM) is a
RT   negative regulator of insulin signaling in primary hepatocytes and
RT   liver.";
RL   Zool. Sci. 22:169-175(2005).
RN   [36]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH IGF1R.
RX   PubMed=16831875; DOI=10.1074/jbc.M605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like
RT   growth factor I receptor (IGF-IR) have low insulin and high IGF-1
RT   affinity irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1185; TYR-1189 AND
RP   TYR-1190, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1189, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1354, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-400; TYR-401 AND
RP   SER-407, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [41]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-242 AND ASN-541, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1064; SER-1348 AND
RP   SER-1379, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [43]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-445 AND ASN-920, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [44]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1112, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1005-1310.
RX   MEDLINE=95089813; PubMed=7997262; DOI=10.1038/372746a0;
RA   Hubbard S.R., Wei L., Ellis L., Hendrickson W.A.;
RT   "Crystal structure of the tyrosine kinase domain of the human insulin
RT   receptor.";
RL   Nature 372:746-754(1994).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1005-1310.
RX   MEDLINE=97459943; PubMed=9312016; DOI=10.1093/emboj/16.18.5572;
RA   Hubbard S.R.;
RT   "Crystal structure of the activated insulin receptor tyrosine kinase
RT   in complex with peptide substrate and ATP analog.";
RL   EMBO J. 16:5572-5581(1997).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1005-1310 IN COMPLEX WITH
RP   SH2B2.
RX   PubMed=14690593; DOI=10.1016/S1097-2765(03)00487-8;
RA   Hu J., Liu J., Ghirlando R., Saltiel A.R., Hubbard S.R.;
RT   "Structural basis for recruitment of the adaptor protein APS to the
RT   activated insulin receptor.";
RL   Mol. Cell 12:1379-1389(2003).
RN   [48]
RP   VARIANT IRAN TYPE A SER-762.
RX   MEDLINE=88204915; PubMed=3283938; DOI=10.1126/science.3283938;
RA   Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H.,
RA   Imura H., Bell G.I., Steiner D.F.;
RT   "Insulin-resistant diabetes due to a point mutation that prevents
RT   insulin proreceptor processing.";
RL   Science 240:784-787(1988).
RN   [49]
RP   VARIANT LEPRECHAUNISM GLU-487.
RX   MEDLINE=88204916; PubMed=2834824; DOI=10.1126/science.2834824;
RA   Kadowaki T., Bevins C., Cama A., Ojamaa K., Marcus-Samuels B.,
RA   Kadowaki H., Beitz L., McKeon C., Taylor S.I.;
RT   "Two mutant alleles of the insulin receptor gene in a patient with
RT   extreme insulin resistance.";
RL   Science 240:787-790(1988).
RN   [50]
RP   VARIANT LEPRECHAUNISM PRO-260.
RX   MEDLINE=90060008; PubMed=2479553;
RA   Klinkhamer M.P., Groen N.A., van der Zon G.C.M., Lindhout D.,
RA   Sandkuyl L.A., Krans H.M.J., Moeller W., Maassen J.A.;
RT   "A leucine-to-proline mutation in the insulin receptor in a family
RT   with insulin resistance.";
RL   EMBO J. 8:2503-2507(1989).
RN   [51]
RP   VARIANT IRAN TYPE A VAL-1035.
RX   MEDLINE=89298409; PubMed=2544998; DOI=10.1126/science.2544998;
RA   Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K.,
RA   Accili D., Bevins C., Mikami Y., Matsuura N., Akanuma Y., Takaku F.,
RA   Taylor S.I., Kasuga M.;
RT   "Human diabetes associated with a mutation in the tyrosine kinase
RT   domain of the insulin receptor.";
RL   Science 245:66-68(1989).
RN   [52]
RP   VARIANT IRAN TYPE A THR-1161.
RX   MEDLINE=90368673; PubMed=2168397;
RA   Moller D.E., Yokota A., White M.F., Pazianos A.G., Flier J.S.;
RT   "A naturally occurring mutation of insulin receptor alanine 1134
RT   impairs tyrosine kinase function and is associated with dominantly
RT   inherited insulin resistance.";
RL   J. Biol. Chem. 265:14979-14985(1990).
RN   [53]
RP   CHARACTERIZATION OF VARIANT RMS LYS-42.
RX   MEDLINE=91035445; PubMed=2121734;
RA   Kadowaki T., Kadowaki H., Accili D., Taylor S.I.;
RT   "Substitution of lysine for asparagine at position 15 in the alpha-
RT   subunit of the human insulin receptor. A mutation that impairs
RT   transport of receptors to the cell surface and decreases the affinity
RT   of insulin binding.";
RL   J. Biol. Chem. 265:19143-19150(1990).
RN   [54]
RP   VARIANT RMS LYS-42, VARIANT LEPRECHAUNISM ARG-236, AND VARIANT IRAN
RP   TYPE A SER-489.
RX   MEDLINE=90307970; PubMed=2365819; DOI=10.1172/JCI114693;
RA   Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J.,
RA   Gorden P., Taylor S.I.;
RT   "Five mutant alleles of the insulin receptor gene in patients with
RT   genetic forms of insulin resistance.";
RL   J. Clin. Invest. 86:254-264(1990).
RN   [55]
RP   VARIANT IRAN TYPE A SER-1227.
RX   MEDLINE=91155951; PubMed=1963473;
RA   Moller D.E., Yokota A., Ginsberg-Fellner F., Flier J.S.;
RT   "Functional properties of a naturally occurring Trp1200-->Ser1200
RT   mutation of the insulin receptor.";
RL   Mol. Endocrinol. 4:1183-1191(1990).
RN   [56]
RP   VARIANT GLU-1095.
RX   MEDLINE=91250037; PubMed=2040394;
RA   O'Rahilly S., Choi W.H., Patel P., Turner R.C., Flier J.S.,
RA   Moller D.E.;
RT   "Detection of mutations in insulin-receptor gene in NIDDM patients by
RT   analysis of single-stranded conformation polymorphisms.";
RL   Diabetes 40:777-782(1991).
RN   [57]
RP   VARIANT IRAN TYPE A GLN-1020.
RX   MEDLINE=91161622; PubMed=2002058;
RA   Kusari J., Takata Y., Hatada E., Freidenberg G., Kolterman O.,
RA   Olefsky J.M.;
RT   "Insulin resistance and diabetes due to different mutations in the
RT   tyrosine kinase domain of both insulin receptor gene alleles.";
RL   J. Biol. Chem. 266:5260-5267(1991).
RN   [58]
RP   VARIANT INS RESISTANCE ILE-1180.
RX   MEDLINE=91365848; PubMed=1890161;
RA   Cama A., de la Luz Sierra M., Ottini L., Kadowaki T., Gorden P.,
RA   Imperato-Mcginley J., Taylor S.I.;
RT   "A mutation in the tyrosine kinase domain of the insulin receptor
RT   associated with insulin resistance in an obese woman.";
RL   J. Clin. Endocrinol. Metab. 73:894-901(1991).
RN   [59]
RP   VARIANTS LEPRECHAUNISM ALA-55 AND ARG-393.
RX   MEDLINE=92299170; PubMed=1607067;
RA   Barbetti F., Gejman P.V., Taylor S.I., Raben N., Cama A., Bonora E.,
RA   Pizzo P., Moghetti P., Muggeo M., Roth J.;
RT   "Detection of mutations in insulin receptor gene by denaturing
RT   gradient gel electrophoresis.";
RL   Diabetes 41:408-415(1992).
RN   [60]
RP   VARIANT NIDDM GLN-1191.
RX   MEDLINE=92299185; PubMed=1607076;
RA   Cocozza S., Porcellini A., Riccardi G., Monticelli A., Condorelli G.,
RA   Ferrara A., Pianese L., Miele C., Capaldo B., Beguinot F., Varrone S.;
RT   "NIDDM associated with mutation in tyrosine kinase domain of insulin
RT   receptor gene.";
RL   Diabetes 41:521-526(1992).
RN   [61]
RP   VARIANT INS RESISTANCE LEU-1205.
RX   MEDLINE=92225265; PubMed=1563582; DOI=10.1007/BF00400927;
RA   Kim H., Kadowaki H., Sakura H., Odawara M., Momomura K., Takahashi Y.,
RA   Miyazaki Y., Ohtani T., Akanuma Y., Yazaki Y., Kasuga M., Taylor S.I.,
RA   Kadowaki T.;
RT   "Detection of mutations in the insulin receptor gene in patients with
RT   insulin resistance by analysis of single-stranded conformational
RT   polymorphisms.";
RL   Diabetologia 35:261-266(1992).
RN   [62]
RP   VARIANT LEPRECHAUNISM ARG-58.
RX   MEDLINE=92112725; PubMed=1730625;
RA   van der Vorm E.R., van der Zon G.C.M., Moeller W., Krans H.M.J.,
RA   Lindhout D., Maassen J.A.;
RT   "An Arg for Gly substitution at position 31 in the insulin receptor,
RT   linked to insulin resistance, inhibits receptor processing and
RT   transport.";
RL   J. Biol. Chem. 267:66-71(1992).
RN   [63]
RP   VARIANT INS RESISTANCE GLN-1158.
RX   MEDLINE=93109267; PubMed=1470163;
RA   Kasuga M., Kishimoto M., Hashiramoto M., Yonezawa K., Kazumi T.,
RA   Hagino H., Shii K.;
RT   "Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic
RT   loop of insulin receptor observed in insulin resistant diabetes.";
RL   Nihon Geka Gakkai Zasshi 93:968-971(1992).
RN   [64]
RP   VARIANT MET-1012.
RX   MEDLINE=93162359; PubMed=8432414;
RA   Elbein S.C., Sorensen L.K., Schumacher M.C.;
RT   "Methionine for valine substitution in exon 17 of the insulin receptor
RT   gene in a pedigree with familial NIDDM.";
RL   Diabetes 42:429-434(1993).
RN   [65]
RP   VARIANT INS RESISTANCE ASP-1075.
RX   MEDLINE=94063262; PubMed=8243830;
RA   Haruta T., Takata Y., Iwanishi M., Maegawa H., Imamura T., Egawa K.,
RA   Itazu T., Kobayashi M.;
RT   "Ala1048-->Asp mutation in the kinase domain of insulin receptor
RT   causes defective kinase activity and insulin resistance.";
RL   Diabetes 42:1837-1844(1993).
RN   [66]
RP   VARIANT MET-1012.
RX   MEDLINE=93209491; PubMed=8458533; DOI=10.1007/BF00400701;
RA   van der Vorm E.R., Kuipers A., Bonenkamp J.W., Kleijer W.J.,
RA   van Maldergem L., Herwig J., Maassen J.A.;
RT   "Patients with lipodystrophic diabetes mellitus of the Seip-
RT   Berardinelli type, express normal insulin receptors.";
RL   Diabetologia 36:172-174(1993).
RN   [67]
RP   VARIANT INS RESISTANCE LEU-1220.
RX   MEDLINE=93300291; PubMed=8390949; DOI=10.1007/BF00402277;
RA   Iwanishi M., Haruta T., Takata Y., Ishibashi O., Sasaoka T., Egawa K.,
RA   Imamura T., Naitou K., Itazu T., Kobayashi M.;
RT   "A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the
RT   insulin receptor associated with type A syndrome of insulin
RT   resistance.";
RL   Diabetologia 36:414-422(1993).
RN   [68]
RP   VARIANT INS RESISTANCE LEU-220.
RX   MEDLINE=94061041; PubMed=8242067; DOI=10.1093/hmg/2.9.1437;
RA   Carrera P., Cordera R., Ferrari M., Cremonesi L., Taramelli R.,
RA   Andraghetti G., Carducci C., Dozio N., Pozza G., Taylor S.I.,
RA   Micossi P., Barbetti F.;
RT   "Substitution of Leu for Pro-193 in the insulin receptor in a patient
RT   with a genetic form of severe insulin resistance.";
RL   Hum. Mol. Genet. 2:1437-1441(1993).
RN   [69]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLU-1162.
RX   MEDLINE=93216782; PubMed=8096518;
RA   Cama A., de la Luz Sierra M., Quon M.J., Ottini L., Gorden P.,
RA   Taylor S.I.;
RT   "Substitution of glutamic acid for alanine 1135 in the putative
RT   'catalytic loop' of the tyrosine kinase domain of the human insulin
RT   receptor. A mutation that impairs proteolytic processing into subunits
RT   and inhibits receptor tyrosine kinase activity.";
RL   J. Biol. Chem. 268:8060-8069(1993).
RN   [70]
RP   VARIANT INS RESISTANCE VAL-409.
RX   MEDLINE=93266582; PubMed=8388389;
RA   Lebrun C., Baron V., Kaliman P., Gautier N., Dolais-Kitabgi J.,
RA   Taylor S.I., Accili D., van Obberghen E.;
RT   "Antibodies to the extracellular receptor domain restore the hormone-
RT   insensitive kinase and conformation of the mutant insulin receptor
RT   valine 382.";
RL   J. Biol. Chem. 268:11272-11277(1993).
RN   [71]
RP   VARIANT LEPRECHAUNISM MET-146.
RX   MEDLINE=93316277; PubMed=8326490;
RA   Al-Gazali L.I., Khalil M., Devadas K.;
RT   "A syndrome of insulin resistance resembling leprechaunism in five
RT   sibs of consanguineous parents.";
RL   J. Med. Genet. 30:470-475(1993).
RN   [72]
RP   VARIANT LEPRECHAUNISM PRO-113.
RX   MEDLINE=93126382; PubMed=8419945; DOI=10.1073/pnas.90.1.60;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Activation of glucose transport by a natural mutation in the human
RT   insulin receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:60-64(1993).
RN   [73]
RP   VARIANT IRAN TYPE A GLN-1201.
RX   MEDLINE=94116755; PubMed=8288049;
RA   Moller D.E., Cohen O., Yamaguchi Y., Assiz R., Grigorescu F.,
RA   Eberle A., Morrow L.A., Moses A.C., Flier J.S.;
RT   "Prevalence of mutations in the insulin receptor gene in subjects with
RT   features of the type A syndrome of insulin resistance.";
RL   Diabetes 43:247-255(1994).
RN   [74]
RP   VARIANT RMS SYNDROME LEU-350, VARIANTS INS RESISTANCE LEU-1205 AND
RP   GLN-1378, AND VARIANT MET-1012.
RX   MEDLINE=94148142; PubMed=8314008;
RA   Krook A., Kumar S., Laing I., Boulton A.J., Wass J.A., O'Rahilly S.;
RT   "Molecular scanning of the insulin receptor gene in syndromes of
RT   insulin resistance.";
RL   Diabetes 43:357-368(1994).
RN   [75]
RP   CHARACTERIZATION OF VARIANT IRAN TYPE A GLN-1201.
RX   MEDLINE=94364485; PubMed=8082780; DOI=10.1016/0014-5793(94)00876-0;
RA   Moritz W., Froesch E.R., Boeni-Schnetzler M.;
RT   "Functional properties of a heterozygous mutation (Arg1174-->Gln) in
RT   the tyrosine kinase domain of the insulin receptor from a type A
RT   insulin resistant patient.";
RL   FEBS Lett. 351:276-280(1994).
RN   [76]
RP   VARIANT LEPRECHAUNISM SER-439.
RX   MEDLINE=94245758; PubMed=8188715;
RA   van der Vorm E.R., Kuipers A., Kielkopf-Renner S., Krans H.M.J.,
RA   Moller W., Maassen J.A.;
RT   "A mutation in the insulin receptor that impairs proreceptor
RT   processing but not insulin binding.";
RL   J. Biol. Chem. 269:14297-14302(1994).
RN   [77]
RP   CHARACTERIZATION OF VARIANTS INS RESISTANCE ASP-1206 AND LEU-1220.
RX   MEDLINE=95074138; PubMed=7983039;
RA   Imamura T., Takata Y., Sasaoka T., Takada Y., Morioka H., Haruta T.,
RA   Sawa T., Iwanishi M., Hu Y.G., Suzuki Y., Hamada J., Kobayashi M.;
RT   "Two naturally occurring mutations in the kinase domain of insulin
RT   receptor accelerate degradation of the insulin receptor and impair the
RT   kinase activity.";
RL   J. Biol. Chem. 269:31019-31027(1994).
RN   [78]
RP   VARIANT LEPRECHAUNISM MET-146.
RX   MEDLINE=95115010; PubMed=7815442;
RA   Hone J., Accili D., al-Gazali L.I., Lestringant G., Orban T.,
RA   Taylor S.I.;
RT   "Homozygosity for a new mutation (Ile119-->Met) in the insulin
RT   receptor gene in five sibs with familial insulin resistance.";
RL   J. Med. Genet. 31:715-716(1994).
RN   [79]
RP   VARIANT NIDDM ALA-858, AND VARIANT CYS-1361.
RX   MEDLINE=95385853; PubMed=7657032;
RA   Kan M., Kanai F., Iida M., Jinnouchi H., Todaka M., Imanaka T.,
RA   Ito K., Nishioka Y., Ohnishi T., Kamohara S., Hayashi H., Murakami T.,
RA   Kagawa S., Sano H., Hashimoto N., Yoshida S., Makino H., Ebina Y.;
RT   "Frequency of mutations of insulin receptor gene in Japanese patients
RT   with NIDDM.";
RL   Diabetes 44:1081-1086(1995).
RN   [80]
RP   VARIANT LEPRECHAUNISM ASN-308 DEL.
RX   MEDLINE=95263703; PubMed=7538143; DOI=10.1210/jc.80.5.1496;
RA   Longo N., Langley S.D., Griffin L.D., Elsas L.J.;
RT   "Two mutations in the insulin receptor gene of a patient with
RT   leprechaunism: application to prenatal diagnosis.";
RL   J. Clin. Endocrinol. Metab. 80:1496-1501(1995).
RN   [81]
RP   VARIANT PHE-1023.
RX   MEDLINE=97045807; PubMed=8890729;
RA   Moritz W., Boeni-Schnetzler M., Stevens W., Froesch E.R., Levy J.R.;
RT   "In-frame exon 2 deletion in insulin receptor RNA in a family with
RT   extreme insulin resistance in association with defective insulin
RT   binding: a case report.";
RL   Eur. J. Endocrinol. 135:357-363(1996).
RN   [82]
RP   VARIANT LEPRECHAUNISM ASN-308 DEL.
RX   MEDLINE=96225546; PubMed=8636294; DOI=10.1210/jc.81.2.719;
RA   Desbois-Mouthon C., Sert-Langeron C., Magre J., Oreal E., Blivet M.J.,
RA   Flori E., Besmond C., Capeau J., Caron M.;
RT   "Deletion of Asn281 in the alpha-subunit of the human insulin receptor
RT   causes constitutive activation of the receptor and insulin
RT   desensitization.";
RL   J. Clin. Endocrinol. Metab. 81:719-727(1996).
RN   [83]
RP   VARIANT MET-1012.
RX   MEDLINE=97342928; PubMed=9199575;
RA   Hansen L., Hansen T., Clausen J.O., Echwald S.M., Urhammer S.A.,
RA   Rasmussen S.K., Pedersen O.;
RT   "The Val985Met insulin-receptor variant in the Danish Caucasian
RT   population: lack of associations with non-insulin-dependent diabetes
RT   mellitus or insulin resistance.";
RL   Am. J. Hum. Genet. 60:1532-1535(1997).
RN   [84]
RP   VARIANTS INS RESISTANCE GLY-86 AND PRO-89.
RX   MEDLINE=97318853; PubMed=9175790; DOI=10.1006/bbrc.1997.6695;
RA   Rouard M., Macari F., Bouix O., Lautier C., Brun J.F., Lefebvre P.,
RA   Renard E., Bringer J., Jaffiol C., Grigorescu F.;
RT   "Identification of two novel insulin receptor mutations, Asp59Gly and
RT   Leu62Pro, in type A syndrome of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 234:764-768(1997).
RN   [85]
RP   CHARACTERIZATION OF VARIANT LEPRECHAUNISM MET-937.
RX   MEDLINE=97445067; PubMed=9299395; DOI=10.1006/bbrc.1997.7181;
RA   Kadowaki H., Takahashi Y., Ando A., Momomura K., Kaburagi Y.,
RA   Quin J.D., MacCuish A.C., Koda N., Fukushima Y., Taylor S.I.,
RA   Akanuma Y., Yazaki Y., Kadowaki T.;
RT   "Four mutant alleles of the insulin receptor gene associated with
RT   genetic syndromes of extreme insulin resistance.";
RL   Biochem. Biophys. Res. Commun. 237:516-520(1997).
RN   [86]
RP   VARIANTS LEPRECHAUNISM TRP-1119 AND LYS-1206.
RX   MEDLINE=97393350; PubMed=9249867;
RX   DOI=10.1002/(SICI)1097-0223(199707)17:7<657::AID-PD132>3.3.CO;2-#;
RA   Desbois-Mouthon C., Girodon E., Ghanem N., Caron M., Pennerath A.,
RA   Conteville P., Magre J., Besmond C., Goossens M., Capeau J.,
RA   Amselem S.;
RT   "Molecular analysis of the insulin receptor gene for prenatal
RT   diagnosis of leprechaunism in two families.";
RL   Prenat. Diagn. 17:657-663(1997).
RN   [87]
RP   VARIANTS LEPRECHAUNISM TYR-301 AND TRP-1201.
RX   MEDLINE=98366902; PubMed=9703342;
RA   Whitehead J.P., Soos M.A., Jackson R., Tasic V., Kocova M.,
RA   O'Rahilly S.;
RT   "Multiple molecular mechanisms of insulin receptor dysfunction in a
RT   patient with Donohue syndrome.";
RL   Diabetes 47:1362-1364(1998).
RN   [88]
RP   VARIANTS RMS THR-1143 AND TRP-1158.
RX   MEDLINE=99371250; PubMed=10443650; DOI=10.1210/jc.84.8.2623;
RA   Longo N., Wang Y., Pasquali M.;
RT   "Progressive decline in insulin levels in Rabson-Mendenhall
RT   syndrome.";
RL   J. Clin. Endocrinol. Metab. 84:2623-2629(1999).
RN   [89]
RP   VARIANTS INS RESISTANCE LEU-167 AND VAL-1055.
RX   MEDLINE=20195376; PubMed=10733238;
RX   DOI=10.1034/j.1399-0004.2000.570110.x;
RA   Rique S., Nogues C., Ibanez L., Marcos M.V., Ferragut J.,
RA   Carrascosa A., Potau N.;
RT   "Identification of three novel mutations in the insulin receptor gene
RT   in type A insulin resistant patients.";
RL   Clin. Genet. 57:67-69(2000).
RN   [90]
RP   VARIANT INS RESISTANCE TYR-280.
RX   MEDLINE=21159654; PubMed=11260230;
RX   DOI=10.1034/j.1399-0004.2001.590309.x;
RA   Osawa H., Nishimiya T., Ochi M., Niiya T., Onuma H., Kitamuro F.,
RA   Kaino Y., Kida K., Makino H.;
RT   "Identification of novel C253Y missense and Y864X nonsense mutations
RT   in the insulin receptor gene in type A insulin-resistant patients.";
RL   Clin. Genet. 59:194-197(2001).
RN   [91]
RP   VARIANT INS RESISTANCE CYS-279.
RX   MEDLINE=22102292; PubMed=12107746; DOI=10.1007/s00125-002-0798-5;
RA   Hamer I., Foti M., Emkey R., Cordier-Bussat M., Philippe J.,
RA   De Meyts P., Maeder C., Kahn C.R., Carpentier J.-L.;
RT   "An arginine to cysteine(252) mutation in insulin receptors from a
RT   patient with severe insulin resistance inhibits receptor
RT   internalisation but preserves signalling events.";
RL   Diabetologia 45:657-667(2002).
RN   [92]
RP   CHARACTERIZATION OF VARIANTS LEPRECHAUNISM PRO-113; VAL-119; ASN-308
RP   DEL; THR-925 AND TRP-926, AND VARIANTS RMS THR-997; THR-1143; TRP-1158
RP   AND TRP-1201.
RX   MEDLINE=22021354; PubMed=12023989; DOI=10.1093/hmg/11.12.1465;
RA   Longo N., Wang Y., Smith S.A., Langley S.D., DiMeglio L.A.,
RA   Giannella-Neto D.;
RT   "Genotype-phenotype correlation in inherited severe insulin
RT   resistance.";
RL   Hum. Mol. Genet. 11:1465-1475(2002).
RN   [93]
RP   VARIANT LEPRECHAUNISM VAL-362 DEL.
RX   MEDLINE=22426011; PubMed=12538626; DOI=10.1210/en.2002-220815;
RA   George S., Johansen A., Soos M.A., Mortensen H., Gammeltoft S.,
RA   Saudek V., Siddle K., Hansen L., O'Rahilly S.;
RT   "Deletion of V335 from the L2 domain of the insulin receptor results
RT   in a conformationally abnormal receptor that is unable to bind insulin
RT   and causes Donohue's syndrome in a human subject.";
RL   Endocrinology 144:631-637(2003).
RN   [94]
RP   VARIANT IRAN TYPE A HIS-279, VARIANTS LEPRECHAUNISM GLN-120; LEU-350;
RP   ASP-458 AND TRP-1119, CHARACTERIZATION OF VARIANT IRAN TYPE A HIS-279,
RP   AND CHARACTERIZATION OF VARIANTS LEPRECHAUNISM GLN-120 AND ASP-458.
RX   PubMed=12970295; DOI=10.1210/jc.2003-030034;
RA   Maassen J.A., Tobias E.S., Kayserilli H., Tukel T., Yuksel-Apak M.,
RA   D'Haens E., Kleijer W.J., Fery F., van der Zon G.C.M.;
RT   "Identification and functional assessment of novel and known insulin
RT   receptor mutations in five patients with syndromes of severe insulin
RT   resistance.";
RL   J. Clin. Endocrinol. Metab. 88:4251-4257(2003).
RN   [95]
RP   VARIANT HHF5 GLN-1201.
RX   PubMed=15161766;
RA   Hoejlund K., Hansen T., Lajer M., Henriksen J.E., Levin K.,
RA   Lindholm J., Pedersen O., Bech-Nielsen H.;
RT   "A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia
RT   linked to a mutation in the human insulin receptor gene.";
RL   Diabetes 53:1592-1598(2004).
RN   [96]
RP   VARIANTS RMS ARG-236 AND SER-386, AND CHARACTERIZATION OF VARIANTS RMS
RP   ARG-236 AND SER-386.
RX   PubMed=17201797; DOI=10.1111/j.1365-2265.2006.02678.x;
RA   Tuthill A., Semple R.K., Day R., Soos M.A., Sweeney E., Seymour P.J.,
RA   Didi M., O'Rahilly S.;
RT   "Functional characterization of a novel insulin receptor mutation
RT   contributing to Rabson-Mendenhall syndrome.";
RL   Clin. Endocrinol. (Oxf.) 66:21-26(2007).
RN   [97]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-228; ARG-695; SER-811; MET-1012;
RP   VAL-1065 AND ALA-1282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: This receptor binds insulin and has a tyrosine-protein
CC       kinase activity. Isoform Short has a higher affinity for insulin.
CC       Mediates the metabolic functions of insulin. Binding to insulin
CC       stimulates association of the receptor with downstream mediators
CC       including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can
CC       activate PI3K either directly by binding to the p85 regulatory
CC       subunit, or indirectly via IRS1. When present in a hybrid receptor
CC       with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid
CC       receptors composed of IGF1R and INSR isoform Long are activated
CC       with a high affinity by IGF1, with low affinity by IGF2 and not
CC       significantly activated by insulin, and that hybrid receptors
CC       composed of IGF1R and INSR isoform Short are activated by IGF1,
CC       IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid
CC       receptors composed of IGF1R and INSR isoform Long and hybrid
CC       receptors composed of IGF1R and INSR isoform Short have similar
CC       binding characteristics, both bind IGF1 and have a low affinity
CC       for insulin.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Manganese.
CC   -!- ENZYME REGULATION: Autophosphorylation activates the kinase
CC       activity.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chains carry the kinase domain.
CC       Interacts with SORBS1 but dissociates from it following insulin
CC       stimulation. Binds SH2B2. Interacts with the PTB/PID domains of
CC       IRS1 and SHC1 in vitro when autophosphorylated on tyrosine
CC       residues. The sequences surrounding the phosphorylated NPXY motif
CC       contribute differentially to either IRS1 or SHC1 recognition.
CC       Interacts with the SH2 domains of the 85 kDa regulatory subunit of
CC       PI3K (PIK3R1) in vitro, when autophosphorylated on tyrosine
CC       residues. Interacts with SOCS7. Forms a hybrid receptor with
CC       IGF1R, the hybrid is a tetramer consisting of 1 alpha chain and 1
CC       beta chain of INSR and 1 alpha chain and 1 beta chain of IGF1R.
CC       Interacts with CAV2 (tyrosine-phosphorylated form); the
CC       interaction is increased with 'Tyr-27'phosphorylation of CAV2.
CC       Interacts with ARRB2 (By similarity). Interacts with GRB10; this
CC       interaction blocks the association between IRS1/IRS2 and INSR,
CC       significantly reduces insulin-stimulated tyrosine phosphorylation
CC       of IRS1 and IRS2 and thus decreases insulin signaling.
CC   -!- INTERACTION:
CC       P18031:PTPN1; NbExp=1; IntAct=EBI-475899, EBI-968788;
CC       Q05209:PTPN12; NbExp=1; IntAct=EBI-475899, EBI-2266035;
CC       P23467:PTPRB; NbExp=1; IntAct=EBI-475899, EBI-1265766;
CC       P08575:PTPRC; NbExp=1; IntAct=EBI-475899, EBI-1341;
CC       P23470:PTPRG; NbExp=1; IntAct=EBI-475899, EBI-2258115;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-475899, EBI-2264500;
CC       Q15262:PTPRK; NbExp=1; IntAct=EBI-475899, EBI-474052;
CC       Q16827:PTPRO; NbExp=1; IntAct=EBI-475899, EBI-723739;
CC       Q9BX66:SORBS1; NbExp=1; IntAct=EBI-475899, EBI-433642;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long; Synonyms=HIR-B;
CC         IsoId=P06213-1; Sequence=Displayed;
CC       Name=Short; Synonyms=HIR-A;
CC         IsoId=P06213-2; Sequence=VSP_002898;
CC   -!- TISSUE SPECIFICITY: Found as a hybrid receptor with IGF1R in
CC       muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma,
CC       fibroblasts, spleen and placenta (at protein level). Isoform Long
CC       and isoform Short are expressed in the peripheral nerve, kidney,
CC       liver, striated muscle, fibroblasts and skin. Isoform Short is
CC       expressed also in the spleen and lymphoblasts.
CC   -!- PTM: After being transported from the endoplasmic reticulum to the
CC       Golgi apparatus, the single glycosylated precursor is further
CC       glycosylated and then cleaved, followed by its transport to the
CC       plasma membrane.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to
CC       insulin.
CC   -!- PTM: Phosphorylation of Tyr-999 is required for IRS1- and SHC1-
CC       binding.
CC   -!- PTM: Dephosphorylated by PTPRE on Tyr-999, Tyr-1185, Tyr-1189 and
CC       Tyr-1190 residues.
CC   -!- DISEASE: Defects in INSR are the cause of insulin resistance (Ins
CC       resistance) [MIM:125853].
CC   -!- DISEASE: Defects in INSR are the cause of Rabson-Mendenhall
CC       syndrome (RMS) [MIM:262190]; also known as Mendenhall syndrome.
CC       RMS is a severe insulin resistance syndrome characterized by
CC       insulin-resistant diabetes mellitus with pineal hyperplasia and
CC       somatic abnormalities. Typical features include coarse, senile-
CC       appearing facies, dental and skin abnormalities, abdominal
CC       distension, and phallic enlargement. Inheritance is autosomal
CC       recessive.
CC   -!- DISEASE: Defects in INSR are the cause of leprechaunism
CC       [MIM:246200]; also known as Donohue syndrome. Leprechaunism
CC       represents the most severe form of insulin resistance syndrome,
CC       characterized by intrauterine and postnatal growth retardation and
CC       death in early infancy. Inheritance is autosomal recessive.
CC   -!- DISEASE: Defects in INSR may be associated with noninsulin-
CC       dependent diabetes mellitus (NIDDM) [MIM:125853]; also known as
CC       diabetes mellitus type 2.
CC   -!- DISEASE: Defects in INSR are the cause of familial
CC       hyperinsulinemic hypoglycemia type 5 (HHF5) [MIM:609968]. Familial
CC       hyperinsulinemic hypoglycemia [MIM:256450], also referred to as
CC       congenital hyperinsulinism, nesidioblastosis, or persistent
CC       hyperinsulinemic hypoglycemia of infancy (PPHI), is the most
CC       common cause of persistent hypoglycemia in infancy and is due to
CC       defective negative feedback regulation of insulin secretion by low
CC       glucose levels.
CC   -!- DISEASE: Defects in INSR are the cause of insulin-resistant
CC       diabetes mellitus with acanthosis nigricans type A (IRAN type A)
CC       [MIM:610549]. This syndrome is characterized by the association of
CC       severe insulin resistance (manifested by marked hyperinsulinemia
CC       and a failure to respond to exogenous insulin) with the skin
CC       lesion acanthosis nigricans and ovarian hyperandrogenism in
CC       adolescent female subjects. Women frequently present with
CC       hirsutism, acne, amenorrhea or oligomenorrhea, and virilization.
CC       This syndrome is different from the type B that has been
CC       demonstrated to be secondary to the presence of circulating
CC       autoantibodies against the insulin receptor.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily.
CC   -!- SIMILARITY: Contains 3 fibronectin type-III domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Insulin receptor entry;
CC       URL="http://en.wikipedia.org/wiki/Insulin_receptor";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/INSR";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M10051; AAA59174.1; -; mRNA.
DR   EMBL; X02160; CAA26096.1; -; mRNA.
DR   EMBL; M32972; AAA59452.1; -; Genomic_DNA.
DR   EMBL; M23100; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32823; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32824; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32825; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32826; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32827; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32828; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32829; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32830; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32831; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32832; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32833; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32834; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32835; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32836; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32837; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32838; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32839; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32840; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32841; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; M32842; AAA59452.1; JOINED; Genomic_DNA.
DR   EMBL; AC010311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010526; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010606; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC125387; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117172; AAI17173.1; -; mRNA.
DR   EMBL; J03466; AAA59175.1; -; Genomic_DNA.
DR   EMBL; J05043; AAA59190.1; -; Genomic_DNA.
DR   EMBL; M76592; AAC37604.1; -; Genomic_DNA.
DR   EMBL; AB208861; BAD92098.1; -; mRNA.
DR   EMBL; M24555; AAA59178.1; -; mRNA.
DR   EMBL; M29929; AAA59176.1; -; Genomic_DNA.
DR   EMBL; M29930; AAA59177.1; -; Genomic_DNA.
DR   EMBL; M27197; AAA86791.1; -; Genomic_DNA.
DR   EMBL; M27195; AAA86791.1; JOINED; Genomic_DNA.
DR   IPI; IPI00025803; -.
DR   IPI; IPI00220325; -.
DR   PIR; A37348; INHUR.
DR   RefSeq; NP_000199.2; -.
DR   RefSeq; NP_001073285.1; -.
DR   UniGene; Hs.465744; -.
DR   PDB; 1GAG; X-ray; 2.70 A; A=1005-1310.
DR   PDB; 1I44; X-ray; 2.40 A; A=1005-1310.
DR   PDB; 1IR3; X-ray; 1.90 A; A=1005-1310.
DR   PDB; 1IRK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 1P14; X-ray; 1.90 A; A=1005-1298.
DR   PDB; 1RQQ; X-ray; 2.60 A; A/B=1005-1310.
DR   PDB; 2AUH; X-ray; 3.20 A; A=1005-1310.
DR   PDB; 2B4S; X-ray; 2.30 A; B/D=1005-1310.
DR   PDB; 2DTG; X-ray; 3.80 A; E=28-943.
DR   PDB; 2HR7; X-ray; 2.32 A; A/B=28-512.
DR   PDB; 2Z8C; X-ray; 3.25 A; A=1009-1310.
DR   PDB; 3BU3; X-ray; 1.65 A; A=1005-1310.
DR   PDB; 3BU5; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3BU6; X-ray; 1.95 A; A=1005-1310.
DR   PDB; 3EKK; X-ray; 2.10 A; A=1005-1310.
DR   PDB; 3EKN; X-ray; 2.20 A; A=1005-1310.
DR   PDB; 3ETA; X-ray; 2.60 A; A/B=1017-1322.
DR   PDB; 3LOH; X-ray; 3.80 A; E=28-956.
DR   PDBsum; 1GAG; -.
DR   PDBsum; 1I44; -.
DR   PDBsum; 1IR3; -.
DR   PDBsum; 1IRK; -.
DR   PDBsum; 1P14; -.
DR   PDBsum; 1RQQ; -.
DR   PDBsum; 2AUH; -.
DR   PDBsum; 2B4S; -.
DR   PDBsum; 2DTG; -.
DR   PDBsum; 2HR7; -.
DR   PDBsum; 2Z8C; -.
DR   PDBsum; 3BU3; -.
DR   PDBsum; 3BU5; -.
DR   PDBsum; 3BU6; -.
DR   PDBsum; 3EKK; -.
DR   PDBsum; 3EKN; -.
DR   PDBsum; 3ETA; -.
DR   PDBsum; 3LOH; -.
DR   ProteinModelPortal; P06213; -.
DR   DIP; DIP-480N; -.
DR   DIP; DIP-6025N; -.
DR   IntAct; P06213; 26.
DR   MINT; MINT-1516246; -.
DR   STRING; P06213; -.
DR   PhosphoSite; P06213; -.
DR   PRIDE; P06213; -.
DR   Ensembl; ENST00000302850; ENSP00000303830; ENSG00000171105.
DR   GeneID; 3643; -.
DR   KEGG; hsa:3643; -.
DR   UCSC; uc002mgd.1; human.
DR   CTD; 3643; -.
DR   GeneCards; GC19M007067; -.
DR   H-InvDB; HIX0040111; -.
DR   HGNC; HGNC:6091; INSR.
DR   HPA; CAB013113; -.
DR   MIM; 125853; phenotype.
DR   MIM; 147670; gene.
DR   MIM; 246200; phenotype.
DR   MIM; 262190; phenotype.
DR   MIM; 609968; phenotype.
DR   MIM; 610549; phenotype.
DR   Orphanet; 2297; Insulin-resistance syndrome type A.
DR   Orphanet; 508; Leprechaunism.
DR   Orphanet; 657; Persistent hyperinsulinemic hypoglycemia of infancy.
DR   Orphanet; 769; Rabson-Mendenhall syndrome.
DR   PharmGKB; PA202; -.
DR   eggNOG; prNOG17961; -.
DR   HOGENOM; HBG316019; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P06213; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; insulin_pathway; Insulin Pathway.
DR   Pathway_Interaction_DB; insulin_glucose_pathway; Insulin-mediated glucose transport.
DR   Pathway_Interaction_DB; mtor_4pathway; mTOR signaling pathway.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_9470; Signaling by FGFR.
DR   DrugBank; DB00047; Insulin Glargine recombinant.
DR   DrugBank; DB00030; Insulin recombinant.
DR   DrugBank; DB00071; Insulin, porcine.
DR   ArrayExpress; P06213; -.
DR   Bgee; P06213; -.
DR   CleanEx; HS_INSR; -.
DR   Genevestigator; P06213; -.
DR   GermOnline; ENSG00000171105; Homo sapiens.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0010008; C:endosome membrane; EXP:Reactome.
DR   GO; GO:0005899; C:insulin receptor complex; IMP:BHF-UCL.
DR   GO; GO:0005792; C:microsome; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0005525; F:GTP binding; IDA:BHF-UCL.
DR   GO; GO:0043559; F:insulin binding; IDA:UniProtKB.
DR   GO; GO:0005009; F:insulin receptor activity; IDA:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IPI:BHF-UCL.
DR   GO; GO:0031995; F:insulin-like growth factor II binding; IPI:BHF-UCL.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043548; F:phosphoinositide 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0051425; F:PTB domain binding; IPI:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; IDA:BHF-UCL.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IDA:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0048639; P:positive regulation of developmental growth; IMP:BHF-UCL.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IDA:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosyntheti...; IDA:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolysis; IMP:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPKKK cascade; IMP:BHF-UCL.
DR   GO; GO:0045840; P:positive regulation of mitosis; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynt...; IMP:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein amino acid p...; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B sig...; IMP:BHF-UCL.
DR   GO; GO:0060267; P:positive regulation of respiratory burst; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:UniProtKB.
DR   GO; GO:0045995; P:regulation of embryonic development; IMP:BHF-UCL.
DR   GO; GO:0032583; P:regulation of gene-specific transcription; IMP:BHF-UCL.
DR   GO; GO:0019087; P:transformation of host cell by virus; IMP:BHF-UCL.
DR   InterPro; IPR000494; EGF_rcpt_L.
DR   InterPro; IPR008957; Fibronectin_III_dom.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR020710; Tyr_kinase_insulin_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR002011; Tyr_prot_kinase_rcpt_2_CS.
DR   PANTHER; PTHR23256:SF176; Tyr_kinase_insulin_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; FN_III-like; 2.
DR   SUPFAM; SSF57184; Grow_fac_recept; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Carbohydrate metabolism; Cleavage on pair of basic residues;
KW   Complete proteome; Diabetes mellitus; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Kinase; Manganese;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Receptor; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     27
FT   CHAIN        28    758       Insulin receptor subunit alpha.
FT                                /FTId=PRO_0000016687.
FT   CHAIN       763   1382       Insulin receptor subunit beta.
FT                                /FTId=PRO_0000016689.
FT   TOPO_DOM    763    956       Extracellular (Potential).
FT   TRANSMEM    957    979       Helical; (Potential).
FT   TOPO_DOM    980   1382       Cytoplasmic (Potential).
FT   DOMAIN      622    695       Fibronectin type-III 1.
FT   DOMAIN      757    842       Fibronectin type-III 2.
FT   DOMAIN      850    946       Fibronectin type-III 3.
FT   DOMAIN     1023   1298       Protein kinase.
FT   NP_BIND    1029   1037       ATP (By similarity).
FT   REGION      996    999       IRS1- and SHC1-binding.
FT   REGION     1361   1364       PIK3R1-binding.
FT   COMPBIAS    182    339       Cys-rich.
FT   ACT_SITE   1159   1159       Proton acceptor (By similarity).
FT   BINDING    1057   1057       ATP.
FT   SITE        996    996       Essential for IRS1-binding and important
FT                                but not critical for SHC1-binding.
FT   SITE        997    997       Essential for IRS1-binding and important
FT                                but not critical for SHC1-binding.
FT   SITE        999    999       Important for biological activity.
FT   MOD_RES     400    400       Phosphoserine.
FT   MOD_RES     401    401       Phosphotyrosine.
FT   MOD_RES     407    407       Phosphoserine.
FT   MOD_RES     992    992       Phosphotyrosine; by autocatalysis
FT                                (Probable).
FT   MOD_RES     999    999       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1011   1011       Phosphotyrosine; by autocatalysis
FT                                (Probable).
FT   MOD_RES    1064   1064       Phosphoserine.
FT   MOD_RES    1112   1112       N6-acetyllysine.
FT   MOD_RES    1185   1185       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1189   1189       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1190   1190       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1348   1348       Phosphoserine.
FT   MOD_RES    1354   1354       Phosphoserine.
FT   MOD_RES    1355   1355       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1361   1361       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1379   1379       Phosphoserine.
FT   CARBOHYD     43     43       N-linked (GlcNAc...).
FT   CARBOHYD     52     52       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    105    105       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    138    138       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    242    242       N-linked (GlcNAc...).
FT   CARBOHYD    282    282       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    322    322       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    364    364       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    424    424       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    445    445       N-linked (GlcNAc...).
FT   CARBOHYD    541    541       N-linked (GlcNAc...).
FT   CARBOHYD    633    633       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    651    651       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    698    698       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    769    769       N-linked (GlcNAc...).
FT   CARBOHYD    782    782       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    920    920       N-linked (GlcNAc...).
FT   CARBOHYD    933    933       N-linked (GlcNAc...) (Potential).
FT   DISULFID    219    228       By similarity.
FT   DISULFID    223    234       By similarity.
FT   DISULFID    235    243       By similarity.
FT   DISULFID    239    252       By similarity.
FT   DISULFID    255    264       By similarity.
FT   DISULFID    268    280       By similarity.
FT   DISULFID    286    293       By similarity.
FT   DISULFID    301    311       By similarity.
FT   DISULFID    315    328       By similarity.
FT   DISULFID    331    335       By similarity.
FT   DISULFID    462    495
FT   DISULFID    551    551       Interchain.
FT   VAR_SEQ     745    756       Missing (in isoform Short).
FT                                /FTId=VSP_002898.
FT   VARIANT       2      2       A -> G (in dbSNP:rs7508518).
FT                                /FTId=VAR_058395.
FT   VARIANT      42     42       N -> K (in RMS; impairs transport to the
FT                                plasma membrane and reduces the affinity
FT                                to bind insulin).
FT                                /FTId=VAR_004079.
FT   VARIANT      55     55       V -> A (in leprechaunism; Verona-1).
FT                                /FTId=VAR_004080.
FT   VARIANT      58     58       G -> R (in leprechaunism; Helmond;
FT                                inhibits processing and transport;
FT                                dbSNP:rs52836744).
FT                                /FTId=VAR_004081.
FT   VARIANT      86     86       D -> G (in Ins resistance; type A).
FT                                /FTId=VAR_015907.
FT   VARIANT      89     89       L -> P (in Ins resistance; type A).
FT                                /FTId=VAR_015908.
FT   VARIANT     113    113       R -> P (in leprechaunism; Atlanta-1;
FT                                abolishes insulin binding).
FT                                /FTId=VAR_004082.
FT   VARIANT     119    119       A -> V (in leprechaunism; markedly
FT                                impairs insulin binding).
FT                                /FTId=VAR_015909.
FT   VARIANT     120    120       L -> Q (in leprechaunism; inhibits
FT                                receptor processing).
FT                                /FTId=VAR_031518.
FT   VARIANT     146    146       I -> M (in leprechaunism; mild).
FT                                /FTId=VAR_015539.
FT   VARIANT     167    167       V -> L (in Ins resistance; type A).
FT                                /FTId=VAR_015910.
FT   VARIANT     171    171       Y -> H (in dbSNP:rs1051692).
FT                                /FTId=VAR_058396.
FT   VARIANT     220    220       P -> L (in Ins resistance; severe).
FT                                /FTId=VAR_004083.
FT   VARIANT     228    228       C -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041429.
FT   VARIANT     236    236       H -> R (in leprechaunism; Winnipeg; in
FT                                one patient with in RMS heterozygous
FT                                compound with S-386; may impair receptor
FT                                processing).
FT                                /FTId=VAR_004084.
FT   VARIANT     260    260       L -> P (in leprechaunism; Geldeimalsen).
FT                                /FTId=VAR_004085.
FT   VARIANT     279    279       R -> C (in Ins resistance; severe;
FT                                inhibits receptor internalization).
FT                                /FTId=VAR_015540.
FT   VARIANT     279    279       R -> H (in IRAN type A; interferes with
FT                                receptor processing).
FT                                /FTId=VAR_031519.
FT   VARIANT     280    280       C -> Y (in Ins resistance; type A).
FT                                /FTId=VAR_015911.
FT   VARIANT     301    301       C -> Y (in leprechaunism).
FT                                /FTId=VAR_015912.
FT   VARIANT     308    308       Missing (in leprechaunism; abolishes
FT                                insulin binding).
FT                                /FTId=VAR_015913.
FT   VARIANT     350    350       S -> L (in RMS and leprechaunism).
FT                                /FTId=VAR_015914.
FT   VARIANT     362    362       Missing (in leprechaunism).
FT                                /FTId=VAR_015541.
FT   VARIANT     386    386       G -> S (in RMS; may impair receptor
FT                                processing).
FT                                /FTId=VAR_031520.
FT   VARIANT     393    393       G -> R (in leprechaunism; Verona-1).
FT                                /FTId=VAR_004086.
FT   VARIANT     409    409       F -> V (in Ins resistance; severe).
FT                                /FTId=VAR_004087.
FT   VARIANT     439    439       W -> S (in leprechaunism; impairs
FT                                transport of the receptor to the cell
FT                                surface).
FT                                /FTId=VAR_015542.
FT   VARIANT     448    448       I -> T (in dbSNP:rs1051691).
FT                                /FTId=VAR_015915.
FT   VARIANT     458    458       N -> D (in leprechaunism; partially
FT                                inhibits receptor processing and
FT                                autophosphorylation; strongly impairs ERK
FT                                phosphorylation; induces wild-type levels
FT                                of IRS-1 phosphorylation).
FT                                /FTId=VAR_031521.
FT   VARIANT     487    487       K -> E (in leprechaunism; ARK-1;
FT                                dbSNP:rs28933083).
FT                                /FTId=VAR_004088.
FT   VARIANT     489    489       N -> S (in IRAN type A;
FT                                dbSNP:rs28933085).
FT                                /FTId=VAR_004089.
FT   VARIANT     492    492       Q -> K (in dbSNP:rs1131851).
FT                                /FTId=VAR_015916.
FT   VARIANT     695    695       Q -> R (in dbSNP:rs55906835).
FT                                /FTId=VAR_041430.
FT   VARIANT     762    762       R -> S (in IRAN type A).
FT                                /FTId=VAR_004090.
FT   VARIANT     811    811       G -> S (in dbSNP:rs35045353).
FT                                /FTId=VAR_041431.
FT   VARIANT     830    830       P -> L (in dbSNP:rs2162771).
FT                                /FTId=VAR_055986.
FT   VARIANT     858    858       T -> A (in NIDDM).
FT                                /FTId=VAR_015917.
FT   VARIANT     925    925       I -> T (in leprechaunism; abolishes
FT                                insulin binding).
FT                                /FTId=VAR_015918.
FT   VARIANT     926    926       R -> W (in leprechaunism; markedly
FT                                impairs insulin binding).
FT                                /FTId=VAR_015919.
FT   VARIANT     937    937       T -> M (in leprechaunism; impaired
FT                                receptor processing).
FT                                /FTId=VAR_015920.
FT   VARIANT     997    997       P -> T (in RMS; reduces insulin binding).
FT                                /FTId=VAR_015921.
FT   VARIANT    1012   1012       V -> M (rare polymorphism;
FT                                dbSNP:rs1799816).
FT                                /FTId=VAR_004091.
FT   VARIANT    1020   1020       R -> Q (in IRAN type A).
FT                                /FTId=VAR_004092.
FT   VARIANT    1023   1023       I -> F.
FT                                /FTId=VAR_015922.
FT   VARIANT    1035   1035       G -> V (in IRAN type A).
FT                                /FTId=VAR_004093.
FT   VARIANT    1055   1055       A -> V (in Ins resistance; type A).
FT                                /FTId=VAR_015923.
FT   VARIANT    1065   1065       L -> V (in dbSNP:rs56395521).
FT                                /FTId=VAR_041432.
FT   VARIANT    1075   1075       A -> D (in Ins resistance; type A).
FT                                /FTId=VAR_004094.
FT   VARIANT    1095   1095       K -> E (in a NIDDM subject).
FT                                /FTId=VAR_015924.
FT   VARIANT    1119   1119       R -> W (in leprechaunism).
FT                                /FTId=VAR_015925.
FT   VARIANT    1143   1143       I -> T (in RMS; reduces insulin binding).
FT                                /FTId=VAR_015926.
FT   VARIANT    1158   1158       R -> Q (in Ins resistance).
FT                                /FTId=VAR_015927.
FT   VARIANT    1158   1158       R -> W (in RMS; abolishes insulin
FT                                binding).
FT                                /FTId=VAR_015928.
FT   VARIANT    1161   1161       A -> T (in IRAN type A;
FT                                dbSNP:rs28933084).
FT                                /FTId=VAR_004095.
FT   VARIANT    1162   1162       A -> E (in IRAN type A; impairs
FT                                proteolytic processing).
FT                                /FTId=VAR_004096.
FT   VARIANT    1180   1180       M -> I (in Ins resistance).
FT                                /FTId=VAR_004097.
FT   VARIANT    1191   1191       R -> Q (in NIDDM).
FT                                /FTId=VAR_004098.
FT   VARIANT    1201   1201       R -> Q (in HHF5 and IRAN type A;
FT                                interferes with kinase activation by
FT                                insulin; dbSNP:rs28933086).
FT                                /FTId=VAR_015929.
FT   VARIANT    1201   1201       R -> W (in leprechaunism and RMS; reduces
FT                                insulin binding possibly due to reduced
FT                                receptor levels on the cell surface).
FT                                /FTId=VAR_015930.
FT   VARIANT    1205   1205       P -> L (in Ins resistance; type A;
FT                                moderate).
FT                                /FTId=VAR_004099.
FT   VARIANT    1206   1206       E -> D (in Ins resistance; type A;
FT                                accelerates degradation of the protein
FT                                and impairs kinase activity).
FT                                /FTId=VAR_015931.
FT   VARIANT    1206   1206       E -> K (in leprechaunism).
FT                                /FTId=VAR_015932.
FT   VARIANT    1220   1220       W -> L (in Ins resistance; type A;
FT                                accelerates degradation of the protein
FT                                and impairs kinase activity;
FT                                dbSNP:rs52800171).
FT                                /FTId=VAR_004100.
FT   VARIANT    1227   1227       W -> S (in IRAN type A).
FT                                /FTId=VAR_004101.
FT   VARIANT    1282   1282       T -> A (in dbSNP:rs55875349).
FT                                /FTId=VAR_041433.
FT   VARIANT    1361   1361       Y -> C (in dbSNP:rs13306449).
FT                                /FTId=VAR_015933.
FT   VARIANT    1378   1378       R -> Q (in Ins resistance; type A;
FT                                dbSNP:rs52826008).
FT                                /FTId=VAR_015934.
FT   MUTAGEN     991    991       L->A: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT   MUTAGEN     992    992       Y->A: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT   MUTAGEN     996    997       NP->AA: Abolishes interaction with IRS1.
FT                                Severely disrupts, but does not abolish
FT                                interaction with SHC1.
FT   MUTAGEN     996    996       N->A: Abolishes interaction with IRS1 and
FT                                significantly reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                PIK3R1.
FT   MUTAGEN     997    997       P->A: Abolishes interaction with IRS1 and
FT                                significantly reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                PIK3R1.
FT   MUTAGEN     998    998       E->A: Does not affect interaction with
FT                                IRS1, SHC1 or PIK3R1.
FT   MUTAGEN     999    999       Y->E: Abolishes interaction with IRS1 and
FT                                SHC1.
FT   MUTAGEN     999    999       Y->F: Has no effect on insulin-stimulated
FT                                autophosphorylation, but inhibits the
FT                                biological activity of the receptor.
FT                                Abolishes interaction with IRS1 and
FT                                almost completely prevents interaction
FT                                with SHC1. Has no effect on interaction
FT                                with PIK3R1.
FT   MUTAGEN    1000   1000       L->A,R: Severely reduces interaction with
FT                                SHC1. Has no effect on interaction with
FT                                IRS1.
FT   MUTAGEN    1002   1002       A->D: Reduces interaction with IRS1 but
FT                                has no effect on interaction with SHC1.
FT   MUTAGEN    1057   1057       K->A: Abolishes the kinase activity and
FT                                abolishes interaction with IRS1, SHC1 and
FT                                PIK3R1.
FT   MUTAGEN    1057   1057       K->M,R: Abolishes the kinase activity.
FT   CONFLICT    601    601       D -> N (in Ref. 19; AA sequence).
FT   CONFLICT    830    830       P -> E (in Ref. 19; AA sequence).
FT   CONFLICT   1278   1278       K -> N (in Ref. 2; CAA26096).
FT   STRAND       33     42
FT   HELIX        45     50
FT   STRAND       53     65
FT   HELIX        70     72
FT   TURN         73     75
FT   STRAND       83     86
FT   STRAND       88     93
FT   TURN        100    102
FT   STRAND      118    124
FT   STRAND      141    149
FT   HELIX       160    162
FT   STRAND      171    175
FT   HELIX       176    178
FT   TURN        187    192
FT   STRAND      199    201
FT   STRAND      204    206
FT   STRAND      209    211
FT   HELIX       221    223
FT   STRAND      243    247
FT   STRAND      251    260
FT   STRAND      263    267
FT   STRAND      273    275
FT   TURN        276    278
FT   STRAND      279    281
FT   HELIX       283    295
FT   STRAND      298    300
FT   STRAND      305    307
FT   STRAND      310    314
FT   STRAND      319    321
FT   STRAND      327    330
FT   STRAND      332    334
FT   STRAND      338    348
FT   HELIX       351    355
FT   TURN        356    359
FT   STRAND      361    369
FT   HELIX       377    385
FT   STRAND      390    393
FT   STRAND      395    399
FT   STRAND      404    406
FT   TURN        422    424
FT   STRAND      425    430
FT   TURN        441    443
FT   STRAND      452    458
FT   HELIX       463    472
FT   TURN        476    478
FT   TURN        481    483
FT   STRAND      486    490
FT   STRAND      513    515
FT   STRAND      521    523
FT   STRAND      527    530
FT   STRAND      534    536
FT   TURN        539    541
FT   STRAND      564    567
FT   STRAND      572    574
FT   STRAND      577    580
FT   STRAND      591    595
FT   STRAND      626    632
FT   STRAND      634    636
FT   STRAND      638    643
FT   STRAND      648    651
FT   STRAND      653    656
FT   STRAND      659    662
FT   STRAND      672    674
FT   STRAND      805    809
FT   STRAND      817    820
FT   STRAND      823    826
FT   STRAND      828    831
FT   STRAND      840    843
FT   STRAND      861    865
FT   STRAND      881    884
FT   STRAND      889    893
FT   STRAND      902    904
FT   STRAND      918    921
FT   STRAND      927    929
FT   TURN       1014   1016
FT   HELIX      1020   1022
FT   STRAND     1023   1031
FT   STRAND     1033   1043
FT   STRAND     1050   1058
FT   HELIX      1065   1078
FT   STRAND     1089   1093
FT   STRAND     1095   1098
FT   STRAND     1100   1104
FT   HELIX      1111   1117
FT   HELIX      1133   1152
FT   HELIX      1162   1164
FT   STRAND     1165   1167
FT   STRAND     1173   1175
FT   HELIX      1200   1202
FT   HELIX      1205   1210
FT   HELIX      1215   1230
FT   TURN       1236   1239
FT   HELIX      1242   1250
FT   HELIX      1263   1272
FT   HELIX      1277   1279
FT   HELIX      1283   1290
FT   HELIX      1291   1293
FT   HELIX      1298   1301
FT   HELIX      1307   1309
SQ   SEQUENCE   1382 AA;  156333 MW;  709A955660739066 CRC64;
     MATGGRRGAA AAPLLVAVAA LLLGAAGHLY PGEVCPGMDI RNNLTRLHEL ENCSVIEGHL
     QILLMFKTRP EDFRDLSFPK LIMITDYLLL FRVYGLESLK DLFPNLTVIR GSRLFFNYAL
     VIFEMVHLKE LGLYNLMNIT RGSVRIEKNN ELCYLATIDW SRILDSVEDN YIVLNKDDNE
     ECGDICPGTA KGKTNCPATV INGQFVERCW THSHCQKVCP TICKSHGCTA EGLCCHSECL
     GNCSQPDDPT KCVACRNFYL DGRCVETCPP PYYHFQDWRC VNFSFCQDLH HKCKNSRRQG
     CHQYVIHNNK CIPECPSGYT MNSSNLLCTP CLGPCPKVCH LLEGEKTIDS VTSAQELRGC
     TVINGSLIIN IRGGNNLAAE LEANLGLIEE ISGYLKIRRS YALVSLSFFR KLRLIRGETL
     EIGNYSFYAL DNQNLRQLWD WSKHNLTITQ GKLFFHYNPK LCLSEIHKME EVSGTKGRQE
     RNDIALKTNG DQASCENELL KFSYIRTSFD KILLRWEPYW PPDFRDLLGF MLFYKEAPYQ
     NVTEFDGQDA CGSNSWTVVD IDPPLRSNDP KSQNHPGWLM RGLKPWTQYA IFVKTLVTFS
     DERRTYGAKS DIIYVQTDAT NPSVPLDPIS VSNSSSQIIL KWKPPSDPNG NITHYLVFWE
     RQAEDSELFE LDYCLKGLKL PSRTWSPPFE SEDSQKHNQS EYEDSAGECC SCPKTDSQIL
     KELEESSFRK TFEDYLHNVV FVPRKTSSGT GAEDPRPSRK RRSLGDVGNV TVAVPTVAAF
     PNTSSTSVPT SPEEHRPFEK VVNKESLVIS GLRHFTGYRI ELQACNQDTP EERCSVAAYV
     SARTMPEAKA DDIVGPVTHE IFENNVVHLM WQEPKEPNGL IVLYEVSYRR YGDEELHLCV
     SRKHFALERG CRLRGLSPGN YSVRIRATSL AGNGSWTEPT YFYVTDYLDV PSNIAKIIIG
     PLIFVFLFSV VIGSIYLFLR KRQPDGPLGP LYASSNPEYL SASDVFPCSV YVPDEWEVSR
     EKITLLRELG QGSFGMVYEG NARDIIKGEA ETRVAVKTVN ESASLRERIE FLNEASVMKG
     FTCHHVVRLL GVVSKGQPTL VVMELMAHGD LKSYLRSLRP EAENNPGRPP PTLQEMIQMA
     AEIADGMAYL NAKKFVHRDL AARNCMVAHD FTVKIGDFGM TRDIYETDYY RKGGKGLLPV
     RWMAPESLKD GVFTTSSDMW SFGVVLWEIT SLAEQPYQGL SNEQVLKFVM DGGYLDQPDN
     CPERVTDLMR MCWQFNPKMR PTFLEIVNLL KDDLHPSFPE VSFFHSEENK APESEELEME
     FEDMENVPLD RSSHCQREEA GGRDGGSSLG FKRSYEEHIP YTHMNGGKKN GRILTLPRSN
     PS
//
